Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tomorrow's Earnings call should be interesting and awkward.
Hoping for $20+ realistically 12-15.
Must have been infuriating for Amarin to submit this 14a lol.
@lizzy - thanks much appreciated.
@lizzy I'm with Schwab, and voting has always been electronic and easy. The proxy for Denner sounds like a paper driven process vs electronic tick a box? Hopefully, I'm wrong because I want to vote in favor of Sarissa.
Also looks like this could be a show stopper for proposal 3. I'm sure Denner and legal team are familiar with such challenges.
Quote:
Proposal No 3 Under Section 160 of the Companies Act, at a general meeting of a public company, a motion for the appointment of two or more persons as directors of the Company by a single resolution must not be made unless a resolution that it should be so made has first been agreed to by the General Meeting without any vote being given against it (an “Authorizing Resolution”). The Company believes that an Authorizing Resolution is necessary for Proposal No. 3 to be validly presented and that if such an Authorizing Resolution is not passed, the Sarissa Nominees put forward in Proposal No. 3 cannot be validly elected.
Sounds like the following will discourage retail investors from submitting their proxy.
Quote:
For a proxy to be effective, it must be properly executed and dated and lodged (together with a duly signed and dated power of attorney or other authority (if any) under which it is executed (or a notarially certified copy of such power of attorney or other authority)) at the offices of the Company’s registrars, Equiniti Limited of Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA, England (the “Registrars”) so as to be received by [?] [a.m./p.m.] local time on [?], 2023 (the “Ordinary Share Instruction Date”). Each proxy properly tendered will, unless otherwise directed by the shareholder, be voted “AGAINST” all of the resolutions to be proposed at the General Meeting, and at the discretion of the proxy holder(s) with regard to all other matters that may properly come before the meeting.
Think I'll wait until it's a Penny stock before potentially flushing more good money down the drain, chasing the bottom. Any day now.
Will I look back at this day in two years, and regret not investing more or will I be glad I didn't send more money down this sink hole?
Unfortunately the market doesn’t seem to think so but maybe the market does not yet know the connection with AMRN?
Liz, not sure.
Lizzie, Below is from a conclusion section of the doc. Will see if I can find other interesting tidbits as word translator only allows up to 3900 characters.
Conclusiononstateofsciencepractice Icosapentethylmeetsstateofscienceandpractice in reducing the risk of cardiovascular events in adult statin-treated patients with high cardiovascular risk with elevated triglycerides (at least 1.7 and maximum 5.6 mmol/L) and an established cardiovascular disease or diabetes with at least one cardiovascular risk factor. The Healthcare Institute concludes on the basis of the data that the medicine has added value compared to usual care.
Well you have company. Same here. Thought we were rising from the ashes last few weeks but that was hopeful thinking. Nightmare continues!
Yep, because it was ‘obvious’ V would help with Alzheimer’s.
@could
“Gratifying to see that Denner has not ditched his position, disappointed that he has not added to it either.”
Hopefully he hasn’t added because he is privy to inside info of a buyout in the works and a result would be prohibited from adding.
Can't believe we're steering penny stock status straight in the face.
Yep and if BP offered Amrn 100% premium tomorrow, we would be looking at a grand sp of $2.50!
Thanks Cap. Problem is that with 3 generics now in the market, total GV vs total V scripts are converging faster. At some point total GV scripts will exceed V and the trajectory will continue into a divergence in Generics favor. Forget infringement, just as with patent rights, those in authority don’t give a crap.
Yep, I paid $2600 per 100 shares a few years ago, today I will buy 100 for $200 or less.
The new buzz word at Amrn - “focused”. Too bad the “focus”seems to be on awarding stock options rather stopping this freaking bleeding! Geez.
@Monk - Thanks for the clarification.
@Orb “Received a letter from Aetna that Icosapent ethyl is not on their formulary.”
Assume you meant to say generic Icosapent ethyl?
Bird and for all of us:
REGRET - buying more instead of selling (at least some) when the SP was above 20..
“Now the courts are forced to address this issue to restore balance, fairness and protection to innovators and protect patients from the evergreening of patents and high brand drug costs.”
Based on the results of Amarin’s several court cases in recent years, from District Courts to the Supreme Court, I see no evidence of interest in fairness or concern, for protection of patent rights or patients for that matter - unfortunately for us investors.
Awesome thanks. Thought we would not have video access. Anyone have an audio link as backup?
This seems to be good news for AMRN, is it not? Could explain why PFE have been working with HLS in Canada - Vascepa plan B?
https://www.fiercebiotech.com/biotech/pfizer-ends-3b-drug-dream-despite-phase-2b-success-leaving-regeneron-a-clear-run-at
@rose, yes points appreciated and I realized after my post that Shad was referring to generic V, though abandoning the US market was also mentioned. They have to find a way to at least make US profitable, albeit may be small, and focus on ROW, while we pray for a BO to end our suffering.
Simple answer - because $500+ M in annual revenue matters.
Maybe the owner of the statin is a potential acquirer/partner and negotiations are the moving forward?
Very strange. They are the numbers I'm seeing in your presentation. Anyway not important.
Q2 VTrx per spreadsheet is 1,139,360. Bar chart has 1,086,611.
Q3VTrx per spreadsheet is 1,143,282. Bar chart has 1,062,083.
Q1 is correct.
Thanks Capt. Your Q2 and Q3 numbers in the first bar chart are wrong.
@Study, thanks and just viewed the link. Very encouraging indeed.
Same re disclaimers. At least they were all up big after FDA approval but stayed long like most of us. Unfortunately being up and not taking profit can't be taken to the bank.
@tke it makes me sick that I convinced friends and family back in 2018, that this was a great investment opportunity. Christmas holidays get together was a bit awkward.
Hopefully this will still amount to something but staring down the barrel at 2’s is not exactly uplifting.
Down too deep to keep throwing money at this, while agree it is an opportunity to lower one’s average sp if you have the guts to gamble more.
Zip, BOD stock option grants and low strike prices, are likely plentiful and generous enough, where they don’t have a desire to purchase additional shares with out of pocket funds.
Bad - Single digit BO.
And this is from the Current Treatments page of that site. Would be nice if they added Vascepa somewhere, no? One has to dig much deeper to find it - madness.
Quote:
CURRENT TREATMENTS FOR CARDIOVASCULAR RISK
High cholesterol is a key cardiovascular (CV) risk factor.9 Statins and a newer injectable therapy called PCSK9 inhibitors help lower high cholesterol.15,16
We’ll start with statins, since they’re currently the first-line therapy for cholesterol lowering. Statins have been around since the ‘90s and are proven to help lower LDL-C (bad cholesterol).17
MANY PEOPLE TAKE STATINS FOR THEIR HEART HEALTH. BUT STATINS, ALONG WITH DIET AND EXERCISE, STILL LEAVE PERSISTENT CV RISK (P-CVR).11
If your doctor decides that your bad cholesterol needs to be even lower than what can be achieved with statin therapy, you might be prescribed a PCSK9 inhibitor.15,16 This type of LDL-C lowering therapy has been around since 2015, and in 2019, PCSK9 inhibitors were FDA-approved to reduce the risk of certain CV events.18,19
Unquote
WTH is up with their stupid tweets? What exactly does this company sell again?
My 3.98 might be too optimistic!